Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

20.0%

2 terminated/withdrawn out of 10 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

10%

1 trials in Phase 3/4

Results Transparency

67%

4 of 6 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 1

6(60.0%)

Phase 2

3(30.0%)

Phase 3

1(10.0%)

10Total

Phase 1(6)

Phase 2(3)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT04314843Phase 1Terminated

Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma

Role: collaborator

NCT03374943Phase 1Completed

A Trial of KB004 in Patients With Glioblastoma

Role: collaborator

NCT04351152Phase 3Unknown

Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19

Role: lead

NCT02546284Phase 1Completed

Study of Lenzilumab in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML)

Role: lead

NCT01211691Phase 1Suspended

Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF)

Role: lead

NCT01603277Phase 2Completed

Effect of KB003 in Subjects With Asthma Inadequately Controlled by Corticosteroids

Role: lead

NCT01695343Phase 2Completed

Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment

Role: lead

NCT00995449Phase 2Terminated

Study of KB003 In Biologics-Inadequate Rheumatoid Arthritis

Role: lead

NCT00638365Phase 1Completed

Dose Escalation Study of KB001 in Cystic Fibrosis Patients Infected With Pseudomonas Aeruginosa

Role: lead

NCT00691587Phase 1Completed

Pilot Trial of KB001 in Mechanically-Ventilated Patients Colonized With Pseudomonas Aeruginosa

Role: lead

All 10 trials loaded